Prosecution Insights
Prosecution Insights
Tech Center 3600 • Art Units: 1615 1618 3646
This examiner grants 34% of resolved cases
Examiner Craig presents a difficult path for applicants in Art Unit 1615, with an allowance rate of only 33.8%. This low rate, based on 65 resolved cases, suggests a very rigorous examination standard in Tech Center 3600. The median days to allowance of 1310 further highlights the challenges, showing a very long timeline. These metrics indicate that applicants must be prepared for a long and potentially contentious prosecution process.
However, the interview lift of 25.2% is remarkably high. This suggests that for the 65 resolved cases, an interview was often the only way to move toward an allowance. Given the low 33.8% baseline allowance rate and the long 1310-day median pendency, an interview should be considered an essential part of the prosecution strategy. The 25.2% lift is a powerful indicator that direct communication can overcome the examiner's strict standards. Practitioners should use this data to advocate for early interviews to improve the probability of success and potentially shorten the 1310-day wait for a grant.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18591471 | RADIOPAQUE CROSSLINKED ACRYLAMIDE COPOLYMERS AND USES THEREOF | Non-Final OA | Boston Scientific Scimed, Inc. |
| 17960867 | SULFATE-FREE SHAMPOO COMPOSITION THAT FORMS LYOTROPIC LIQUID CRYSTALS UPON DILUTION | Final Rejection | The Procter & Gamble Company |
| 17634410 | SMART PEPTIDES AND TRANSFORMABLE NANOPARTICLES FOR CANCER IMMUNOTHERAPY | Non-Final OA | The Regents of the University of California |
| 17311180 | HETEROCYCLYL POLYMETHINE IR CHROMOPHORES | Final Rejection | The Regents of the University of California |
| 17438874 | STICKY PARTICLES FOR EFFICIENT IMAGING | Non-Final OA | The Johns Hopkins University |
| 17422667 | ADHESIVE/ADSORPTION SWITCH ON NANOPARTICLES TO INCREASE TUMOR UPTAKE AND DELAY TUMOR CLEARANCE | Non-Final OA | The Johns Hopkins University |
| 16773540 | MATERIALS AND METHODS FOR GENE DELIVERY IN THE HEART | Non-Final OA | Northwestern University |
| 19275772 | ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF | Final Rejection | Fennec Pharmaceuticals, Inc. |
| 17442905 | TETRAPYRROLIC CONJUGATES AND USES THEREOF FOR IMAGING | Final Rejection | The Research Foundation for The State University of New York |
| 17579470 | Methods and kits for diagnosis of cancer and prediction of therapeutic value | Final Rejection | CORNELL UNIVERSITY |
| 18313915 | MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF | Non-Final OA | Crinetics Pharmaceuticals, Inc. |
| 18022708 | COMPOSITIONS AND METHODS FOR G-PROTEIN-COUPLED RECEPTOR 44 DETECTION | Non-Final OA | City of Hope |
| 18315364 | EXOSOME BASED ASSAYS FOR DETERMINING CANDIDATES FOR OSTEOARTHRITIS STEM CELL THERAPY | Final Rejection | CREATIVE MEDICAL TECHNOLOGIES, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy